Valuation: MediciNova, Inc.

Market Cap 69.4M 62.29M 57.51M 52.15M 97.48M 6.59B 98.68M 690M 274M 3.46B 261M 255M 10.96B P/E 2026 *
-5.53x
P/E 2027 * -3.16x
Enterprise Value 69.4M 62.29M 57.51M 52.15M 97.48M 6.59B 98.68M 690M 274M 3.46B 261M 255M 10.96B EV / Sales 2026 *
95.1x
EV / Sales 2027 * 208x
Free-Float
97.14%
Yield 2026 *
-
Yield 2027 * -
1 day+3.19%
1 week+4.74%
Current month-11.83%
1 month-29.67%
3 months+11.05%
6 months+8.60%
Current year+12.74%
1 week 1.38
Extreme 1.38
1.48
1 month 1.36
Extreme 1.358
2.06
Current year 1.22
Extreme 1.22
3.9
1 year 1.17
Extreme 1.168
3.9
3 years 1.12
Extreme 1.12
3.9
5 years 1.12
Extreme 1.12
4.65
10 years 1.12
Extreme 1.12
14.5
Manager TitleAgeSince
Chief Executive Officer 76 2005-07-31
Director of Finance/CFO 49 2022-06-15
Chief Tech/Sci/R&D Officer 60 2011-08-31
Director TitleAgeSince
Chairman 76 2000-09-25
Director/Board Member 60 2019-07-23
Director/Board Member 69 2004-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/25/26
3D Investment Partners Pte. Ltd.
SellCompany -640,000 1.3003%
1/16/26 Free

Chief Technology Officer

350,000 0.7122%
1/16/26 Free

Chief Executive Officer

450,000 0.9156%
Change 5-day change 1-year change 3-year change Capi.($)
+4.74%+4.74%+22.06%-24.65% 69.4M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.80%+10.24%+101.80% 53.59B
+1.59%-0.13%+26.65%+55.94% 44.75B
+2.11%-3.46%+17.75%+99.93% 41.62B
-0.06%-4.15%+220.11%+914.77% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.20%-0.01%+48.52%+142.73% 38.05B
Weighted average by Cap. +2.99%-0.29%+46.91%+159.99%

Financials

2026 *2027 *
Net sales 730K 655K 605K 549K 1.03M 69.34M 1.04M 7.25M 2.88M 36.34M 2.74M 2.68M 115M 333K 299K 276K 250K 468K 31.66M 474K 3.31M 1.32M 16.6M 1.25M 1.22M 52.63M
Net income -12.89M -11.57M -10.69M -9.69M -18.11M -1.22B -18.33M -128M -50.88M -642M -48.4M -47.36M -2.04B -25.98M -23.32M -21.53M -19.52M -36.49M -2.47B -36.94M -258M -103M -1.29B -97.53M -95.44M -4.1B
Net Debt - -
Projected Income Statement - Annual - MediciNova, Inc.
Logo MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Employees
6
Date Price Change Volume
26-10-28 US$1.477 +4.74% 11,995
26-10-27 US$1.410 +0.71% 37,751
26-10-26 US$1.400 +0.72% 89,906
26-10-23 US$1.390 -1.42% 25,509
26-10-22 US$1.410 0.00% 30,488
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - MediciNova, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.410USD
Average target price
8.250USD
Spread / Average Target
+485.11%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MediciNova, Inc.
  1. Stock Market
  2. Stocks
  3. MNOV Stock